Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation

• ClinicalTrials.gov Identifier: NCT03119584
• Recruitment Status: Active, not recruiting
• First Posted: April 18, 2017
• Last Update Posted: February 25, 2020
• Sponsor: Texas Tech University Health Sciences Center, El Paso
• Information provided by (Responsible Party): Irene Sarosiek, Texas Tech University Health Sciences Center, El Paso

Study Description

Brief Summary:

Study includes 5 visits, when all basic clinical information, vital signs, symptoms, and side effects are going to be assessed at each appointment.

Patients are going to be assigned by the computer, to receive an active or non-active drug for 14 days in a first phase. The order will be change during the second phase. The 2 weeks break without our medication will separate these phases. A very close observation regarding safety of our subjects will be implemented by study personnel and clinical investigators.

Condition or disease	Intervention/treatment	Phase
Chronic Constipation; Diabete Mellitus	Drug: linaclotide or placebo	Phase 4

Detailed Description:

The symptoms of chronic constipation are defined as infrequent bowel movements, hard stool, straining during defecation, bloating, abdominal discomfort, and sensation of incomplete evacuation.

Constipation has been reported as a common complication of diabetic neuropathy. A new medication, called linaclotide, was studied on many patients, and it is approved to be on a market for constipated patients. Unfortunately diabetics were not included in these previous studies; hence we designed the project which is going to address the possible benefit of this drug in diabetic population.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 23 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial
• Actual Study Start Date: September 1, 2015
• Estimated Primary Completion Date: October 30, 2020
• Estimated Study Completion Date: January 30, 2021

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 1)28days of linaclotide or placebo; patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.	Drug: linaclotide or placebo; Other Name: Linzess
Active Comparator: 2)28days of linaclotide or placebo; patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.	Drug: linaclotide or placebo; Other Name: Linzess

Outcome Measures

Primary Outcome Measures :

1. Improvement in frequency of bowel movements [ Time Frame: Up to 10 weeks ]
   The primary outcome measure will indicate improvement in frequency of bowel movements (BMs) or not in a mean of available and recordered spontaneous BM (SBMs) over the 28 day treatment period compared to 28 days of placebo.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Type II diabetics.

• Functional Constipation defined by Rome III criteria are as follows: a. At least a 6 months history of constipation.

  b. Less than three spontaneous bowel movements (SBMs) per week. c. At least 25% of stools are lumpy or hard stools as it is described in Bristol Stool Form Scale (BSFS) less than score of 6.

  d. Sensation of incomplete evacuation following at least 25% of bowel movements.

  e. Straining on at least 25% of defecations. f. Sensation of anorectal obstruction/blockage for at least 25% of defecations.

Note: The above criteria are only applicable to spontaneous bowel movements. Patients who have no spontaneous bowel movements (bowel movements are preceded by laxative intake) are considered constipated and are eligible for this study.

• For patients' ≥ 50 years of age, normal colonic anatomy as documented by colonoscopy or double-contrast barium enema, performed within the previous 5 years, based on the American Gastroenterological Association guidelines.
• Patients with confirm diagnosis of Diabetic Autonomic Neuropathy based on results of ANX 3.0, real-time ANS monitoring system will be included in this investigation.
• Patients diagnosed with diabetic peripheral neuropathy and/or symptoms of functional gastroduodenal disorders, such as GERD and functional dyspepsia may participate in a study.

Exclusion Criteria:

• Pregnancy or lactation
• Subjects unwilling to practice adequate contraception throughout the period of screening through 14 days after study termination.
• Loose or watery stools reported in the absence of laxatives for >25% of BMs during the screening period by using Bristol Stool Form Scale (BSFS).
• Use of laxatives 3 days immediately prior to randomization (except fiber or bulking agents) and chronic laxative use during the trial.
• Patients diagnosed with severe, drug refractory gastroparesis (persistent daily vomiting), currently receiving parenteral feeding (N-G, J-G-Tubes), having history of frequent hospitalizations, or being implanted with gastric neurostimulation system.

• Use of any of the following drugs within 3 days prior randomization and during the trial: a. Prokinetic agents (domperidone, metoclopramide, erythromycin).

  b. Medication containing opiates. c. Anti-spasmodic (e.g. Atropine, hyoscamine, scopolamine, glycopyrrolate).

• Hemoglobin A1c>8.2
• Use of illegal drugs.
• Regular consumption of more than 2 drinks of alcohol per day
• Chronic, more than 3/week use of NSAIDs.
• Patients with prolonged straining/push during BMs suggesting severe pelvic floor dysfunction.
• History or current diagnosis of diverticulitis and severe hemorrhoids.
• History of gastric resections, partial colon resection, history of rectocele.
• Existence of any major medical condition such as malignancy, severe renal and liver diseases, which in the decision of PI should be excluded from participation.

Contacts and Locations

Locations

United States, Texas

Texas Tech University Health Sciences Center

El Paso, Texas, United States, 79905

Sponsors and Collaborators

Texas Tech University Health Sciences Center, El Paso

Investigators

• Principal Investigator: Irene Sarosiek, MD; Texas Tech University Health Sciences Center- El Paso, Texas

More Information

• Responsible Party: Irene Sarosiek, Professor of Medicine, Texas Tech University Health Sciences Center, El Paso
• ClinicalTrials.gov Identifier: NCT03119584
• Other Study ID Numbers: E15025
• First Posted: April 18, 2017
• Last Update Posted: February 25, 2020
• Last Verified: February 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Irene Sarosiek, Texas Tech University Health Sciences Center, El Paso:

chronic constipation; diabetes

Additional relevant MeSH terms:

Diabetes Mellitus; Constipation; Signs and Symptoms, Digestive; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Linaclotide; Guanylyl Cyclase C Agonists; Enzyme Activators; Molecular Mechanisms of Pharmacological Action; Gastrointestinal Agents